NCT05966090 - A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults | Biotech Hunter

Enrollment

530

Participants

Timeline

Start Date

July 28, 2023

Primary Completion Date

February 19, 2024

Study Completion Date

July 29, 2024

Conditions

Respiratory Syncytial VirusesRespiratory Syncytial Virus Infections

Interventions

BIOLOGICAL

RSVPreF3 OA investigational vaccine

One dose of RSVPreF3 OA investigational vaccine given intramuscularly on Day 1 (Coadministration group) or Day 31 (Control group).

BIOLOGICAL

HZ/su vaccine

Two doses of HZ/su vaccine given intramuscularly on Day 1 and Day 61.

Trial Locations (31)

33162

GSK Investigational Site, North Miami Beach

33409

GSK Investigational Site, West Palm Beach

36526

GSK Investigational Site, Daphne

40383

GSK Investigational Site, Versailles

70115

GSK Investigational Site, New Orleans

76104

GSK Investigational Site, Fort Worth

78229

GSK Investigational Site, San Antonio

80012

GSK Investigational Site, Aurora

85281

GSK Investigational Site, Tempe

94925

GSK Investigational Site, Corte Madera

31904-8946

GSK Investigational Site, Columbus

L6T 0G1

GSK Investigational Site, Brampton

N1H 1B1

GSK Investigational Site, Guelph

M4G 3E8

GSK Investigational Site, Toronto

M9V 4B4

GSK Investigational Site, Toronto

G1N 4V3

GSK Investigational Site, Québec

G6W 0M5

GSK Investigational Site, Québec

H9R 4S3

GSK Investigational Site, Québec

J7J 2K8

GSK Investigational Site, Québec

J1L 0H8

GSK Investigational Site, Sherbrooke

N7T 4X3

GSK Investigational Site, Sarnia

M3H 5S4

GSK Investigational Site, Toronto